- Home
- What is SourceGenerics?
- What is an Opportunity?
- View Opportunities
- Post Opportunities
- Advertising/Targeting
What is an opportunity?
SourceGenerics showcases opportunities ranging from technology and product dossiers through to portfolios and businesses. And to make your life easier, SourceGenerics focuses on generics products - no more, no less. So whether you want to in-license, out-license, buy or sell opportunities, advertise your services or target the right people, then SourceGenerics is the solution.
Each business opportunity is expected to result in a separate business deal. If you want to strike more than one deal, then you should post a separate opportunity for each potential deal.
LICENSE - BUY - SELL
Opportunities in these segments
- Oral Solid-Dose Products
- Topical Products
- Injectable Products
- Other Finished-Dosage Forms
- Active Pharmaceutical Ingredients (APIs)
- Intermediates
Types of opportunities
- Products
- Ingredients
- Technology
- Intellectual Property
- Businesses
- Dossiers
- Patents
- Distribution Rights
Featured Opportunities
Testimonials
Einar Geir Hreinsson, Vice-President Strategic Projects at Actavis, says:
"We used this channel to reach potential customers and it turned out to be considerably more effective than we had expected. It is invaluable to be able to introduce a new project like Opening Pharma in this way, through a single portal with connections in all directions. This will be our first choice the next time we want to give a new project a good promotion."
Rich DiCicco, Chief Executive Officer of Harvest Moon Pharma, comments:
"Harvest Moon Pharma has listed its complex generics and biosimilars on SourceGenerics for three years. We have received enquiries from 206 companies - including Pfizer, Sanofi, Teva, Stada, Ranbaxy and Sandoz - from 58 countries, and we are very pleased with the results. We intend to keep listing on SourceGenerics indefinitely."
Sanjiv Puri, Chief Executive Officer of Australia's Generic Partners, tells us:
"Within a week of posting our business opportunities on SourceGenerics we had received over 10 quality enquiries from leading generics companies throughout the world."